| Livingston Hospice Care 320 Alpenglow Lane, Livingston, MT, 59047 | |
| (406) 823-6430 |
News Archive
Thousands of Americans are stressed out as they recover from the various natural disasters that shook our country recently. Unfortunately, when people are in these situations the last thing they think about is their health.
The U.S. Food and Drug Administration today announced plans to hold a public meeting on July 19-20, 2010, to discuss how the agency will oversee laboratory-developed tests (LDTs).
Too little covid vaccine and too great a demand: That's what KHN readers from around the country detail in their often exasperating quest to snag a shot, although they are often clearly eligible under their local guidelines and priority system.
Cephalon, Inc. today announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA). The GABITRIL REMS consists of a Medication Guide to inform patients about the potential risks associated with the use of GABITRIL.
› Verified 9 days ago
| Name | Livingston Hospice Care |
|---|---|
| Location | 320 Alpenglow Lane, Livingston, Montana |
| Hospice ID | 271504 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Individual |
| Profit Type | FOR PROFIT |
| SSA county code | 330 |
News Archive
Thousands of Americans are stressed out as they recover from the various natural disasters that shook our country recently. Unfortunately, when people are in these situations the last thing they think about is their health.
The U.S. Food and Drug Administration today announced plans to hold a public meeting on July 19-20, 2010, to discuss how the agency will oversee laboratory-developed tests (LDTs).
Too little covid vaccine and too great a demand: That's what KHN readers from around the country detail in their often exasperating quest to snag a shot, although they are often clearly eligible under their local guidelines and priority system.
Cephalon, Inc. today announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA). The GABITRIL REMS consists of a Medication Guide to inform patients about the potential risks associated with the use of GABITRIL.
› Verified 9 days ago
| NPI Number | 1568430791 |
| Organization Name | Livingston Healthcare |
| Address | 320 Alpenglow Ln Livingston, Montana, 59047 |
| Phone Number | (406) 222-5030 |
News Archive
Thousands of Americans are stressed out as they recover from the various natural disasters that shook our country recently. Unfortunately, when people are in these situations the last thing they think about is their health.
The U.S. Food and Drug Administration today announced plans to hold a public meeting on July 19-20, 2010, to discuss how the agency will oversee laboratory-developed tests (LDTs).
Too little covid vaccine and too great a demand: That's what KHN readers from around the country detail in their often exasperating quest to snag a shot, although they are often clearly eligible under their local guidelines and priority system.
Cephalon, Inc. today announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA). The GABITRIL REMS consists of a Medication Guide to inform patients about the potential risks associated with the use of GABITRIL.
› Verified 9 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 98.4 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 93.5 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 71.0 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 60.0 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 96.8 | 97.3 |
| Patients who got timely treatment for shortness of breath | 96.3 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 96.4 | 93.3 |
News Archive
Thousands of Americans are stressed out as they recover from the various natural disasters that shook our country recently. Unfortunately, when people are in these situations the last thing they think about is their health.
The U.S. Food and Drug Administration today announced plans to hold a public meeting on July 19-20, 2010, to discuss how the agency will oversee laboratory-developed tests (LDTs).
Too little covid vaccine and too great a demand: That's what KHN readers from around the country detail in their often exasperating quest to snag a shot, although they are often clearly eligible under their local guidelines and priority system.
Cephalon, Inc. today announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA). The GABITRIL REMS consists of a Medication Guide to inform patients about the potential risks associated with the use of GABITRIL.
› Verified 9 days ago
| Home Health Aides | 0.9 |
| Counselors | 0.2 |
| Homemakers | 0.1 |
| Medical Social Workers | 0.4 |
| Physicians | 0.05 |
| Registered Nurses | 1.6 |
| Other Personnel | 0.4 |
| Total Employees | 3.65 |
|---|
News Archive
Thousands of Americans are stressed out as they recover from the various natural disasters that shook our country recently. Unfortunately, when people are in these situations the last thing they think about is their health.
The U.S. Food and Drug Administration today announced plans to hold a public meeting on July 19-20, 2010, to discuss how the agency will oversee laboratory-developed tests (LDTs).
Too little covid vaccine and too great a demand: That's what KHN readers from around the country detail in their often exasperating quest to snag a shot, although they are often clearly eligible under their local guidelines and priority system.
Cephalon, Inc. today announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA). The GABITRIL REMS consists of a Medication Guide to inform patients about the potential risks associated with the use of GABITRIL.
› Verified 9 days ago
| Homemakers | 0.3 |
| Total Volunteers | 0.3 |
|---|
News Archive
Thousands of Americans are stressed out as they recover from the various natural disasters that shook our country recently. Unfortunately, when people are in these situations the last thing they think about is their health.
The U.S. Food and Drug Administration today announced plans to hold a public meeting on July 19-20, 2010, to discuss how the agency will oversee laboratory-developed tests (LDTs).
Too little covid vaccine and too great a demand: That's what KHN readers from around the country detail in their often exasperating quest to snag a shot, although they are often clearly eligible under their local guidelines and priority system.
Cephalon, Inc. today announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA). The GABITRIL REMS consists of a Medication Guide to inform patients about the potential risks associated with the use of GABITRIL.
› Verified 9 days ago
| Livingston Hospice Care Location: 320 Alpenglow Lane, Livingston, Montana, 59047 Phone: (406) 823-6430 |